Replimune Group, Inc.: financial statements

REPLNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$19.07

November 20, 2026Market cap $1.8B

What Ploutos Investor adds for Replimune

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 10 fiscal years, from FY2017
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

FY2024–FY2026 fiscal years

Click a line to see it on the chart.

Operating income

LineFY2024FY2025FY2026Average a year
Operating income -$235M-$262M-$320M
Net income -$216M-$247M-$314M
Earnings per share -$3.24-$3.07-$3.38
Earnings per share, basic -$3.24-$3.07-$3.38

Financial statements

REPL's revenue, profits and cash flows from FY2017 to FY2023, 7 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

Debt and obligations

What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.

$28M Leases0.2% Effective tax rate

Leases

Mar 31, 2026

Operating leases

$3.5M

Finance leases

$25M

Average discount rate
10.4%
Lease cost for the year
$1.2M

The liability is the present value of the rent still to pay, at March 31, 2026. It is not counted in the ladder's debt. The filing

Operating lease payments by year

Lease liability by year

Leases

REPL's leases from FY2019 to FY2023, 5 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

From the statutory to the effective tax rate, FY2026

Mar 31, 2026

Statutory rate

21.0%

Effective rate

0.2%

-20.8 pts

The company paid 0.2% in tax on its profit, 20.8 points below the US federal rate (21.0%). Below, the reasons it gives.

Statutory rate

21.0%

Tax credits

+4.9 pts

Foreign rate differential · United Kingdom

+3.2 pts

State and local taxes

+0.8 pts

Change in valuation allowance · United Kingdom

-20.1 pts

Change in valuation allowance · United States

-6.4 pts

Uncertain tax positions

-3.0 pts

Share-based compensation

-0.7 pts

Not itemized in the filing

-0.2 pts

Smaller lines (2)

+0.7 pts

Effective rate

0.2%

One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing

Effective tax rate by year

Effective tax rate by year

The tax rate REPL paid on its profit, from FY2017 to FY2023, 7 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

The metrics a company reports about itself (users, stores, subscribers) are read for S&P 500 companies only.

The full analysis

What do Replimune's filings show?

These are Replimune's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about REPL's financials

Didn't find what you were looking for?

Ask us
How much debt does REPL have?

On March 31, 2026 Replimune had total assets of $332M, debt of $83M and shareholders' equity of $166M.

How much free cash flow does REPL have?

In fiscal FY2026 Replimune had cash from operations of -$280M and spent $4.2M on capital expenditure, leaving -$285M of free cash flow.

Where are the figures from?

From Replimune Group, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.